Natixis’s Cartesian Therapeutics RNAC Stock Holding History

Natixis’s Portfolio RNAC Stock Details RNAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-377	Closed	-$37K	–	1308
2021 Q4	$37K	Hold	377	–	–	﹤0.01%	1199
2021 Q3	$47K	Buy	+377	New	+$45.5K	﹤0.01%	1176

Other funds holding RNAC

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

NanoDimension Woodside, California $24.7M AUM 74.01% 1-Year Est. Return

ECM

Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Natixis's RNAC Position: Q1 2022 in Review

Natixis sold out of Cartesian Therapeutics (RNAC) in Q1 2022, closing a stake of 377 shares — an estimated $37K sold.

Natixis first reported a position in RNAC in Q3 2021 and held it in 2 quarters. The position peaked at $47K in Q3 2021. 102 funds tracked by Wall St. Rank hold RNAC as of Q1 2022.

Natixis reported no remaining Cartesian Therapeutics position as of Q1 2022 after selling out during the quarter.
Natixis sold 377 Cartesian Therapeutics shares in Q1 2022, an estimated $37K.
Natixis first reported a position in Cartesian Therapeutics in Q3 2021 and held it in 2 quarters.
Natixis's Cartesian Therapeutics position peaked at $47K in Q3 2021.
102 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2022.

Based on Natixis's 13F filing for Q1 2022, filed 13 May 2022.